Diagnostic precision and accuracy in interpretation of specimens from cancer screening programs

Seminars in Diagnostic Pathology

Volumn 22, Issue 2, 2005, Pages 147-155

  Foucar, Elliott ^a  

^a NONE

Author keywords

Anatomic pathology; Pathologic screening methods; Preneoplastic lesions

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; ETHICS; EVIDENCE BASED MEDICINE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEALTH PROGRAM; HUMAN; INCIDENCE; MALIGNANT NEOPLASTIC DISEASE; MORPHOLOGY; PAPANICOLAOU TEST; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TUMOR DIAGNOSIS; UTERINE CERVIX CARCINOMA;

DATA INTERPRETATION, STATISTICAL; EARLY DIAGNOSIS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; MASS SCREENING; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; PATHOLOGY, CLINICAL; PREDICTIVE VALUE OF TESTS; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY;

EID: 33646087889     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2006.02.002     Document Type: Article

References (66)

1. Mosca L. C-reactive protein. to screen or not to screen?. N Engl J Med 347 (2002) 1615-1617
2. Rubinstein B: Letters section. Time Magazine. March 11, 2002
3. Walsh P.C. Surgery and the reduction of mortality from prostate cancer. N Engl J Med 347 (2002) 839-840
4. Deligiannis S.T. Still wise to have a mammogram. (letter). The New York Times (2002) March 4. Section A, late edition, p 20
5. Stolberg S.G. Advocates strive to defeat cancer but disagree on methods. The New York Times (2002). http://nytimes.com April 9. Available at http://nytimes.com. Accesssed April 9, 2002
6. Halsted W.S. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 46 (1907) 1-19 Cited by Lerner BH: The Breast Cancer Wars. Hope, Fear, and the Pursuit of a Cure in Twentieth-Century America. New York, NY, Oxford University Press, 2001, p 22
7. Dunn F.B. Value of prostate-specific antigen. are higher levels meaningful?. J Natl Cancer Inst 94 (2002) 415-416
8. Lerner B.H. The Breast Cancer Wars. Hope, Fear, and the Pursuit of a Cure in Twentieth-Century America (2001), Oxford University Press, New York, NY p 47
9. Grimes D.A., and Schulz K.F. Uses and abuses of screening tests. Lancet 359 (2002) 881-884
10. Burstein H.J., Polyak K., Wong J.S., et al. Ductal carcinoma in situ of the breast. N Engl J Med 350 (2004) 1430-1441
11. Foulds L. The experimental study of tumor progression. a review. Cancer Res 14 (1954) 327-339
12. Berry D.A. Benefits and risks of screening mammography for women in their 40's. a statistical appraisal. J Natl Acad Inst 90 (1998) 1431-1439
13. Black W.C., Haggstrom D.A., and Welch H.G. Re. All-cause mortality in randomized trials of cancer screening. (letters to the editor). J Natl Cancer Inst 94 (2002) 861-866
14. Holmberg L., Bill-Axelson A., Helgesen F., et al. A randomized tial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347 (2002) 781-789
15. Klotz L.H. PSAdynia and other PSA-related syndromes: a new epidemic: a case history and taxonomy. Urology 50 (1997) 831-832
16. Tannock I.F. Eradication of a disease. how we cured asymptomatic prostate cancer. Lancet Oncology (2000) pages 17-19, May
17. Smith R. The drugs don't work. (Editor's choice). BMJ Vol 327 (2003). http://bmjjournals.com Available at: http://bmjjournals.com. Accessed December 15, 2003
18. Welch H.G. Book review of: The Last Well Person: How to Stay Well Despite the Health-Care System. By: Nortin M. Hadler. McGill-Queen's University Press, Montreal, 2004. N Engl J Med 352 (2005) 1161-1162
19. Welch H.G., and Mogielnicki J. Presumed benefit. lessons from the American experience with marrow transplantation for breast cancer. BMJ 324 (2002) 1088-1092
20. Pielke R. Better safe than sorry. Is the precautionary principle a useful guide to action? Book review of: The Precautionary Principle in the 20th Century: Late lessons from Early Warnings. Edited by Poul Harremoes, et al. Earthscan, 2002. Nature 419 (2002) 433-434
21. Greene K. Aging well. The Wall Street Journal (2004) Page R9, January 26
22. Holtzman N.A. Expanding newborn screening. How good is the evidence?. JAMA 290 (2003) 2606-2608
23. Marcus A.D. At 32, a decision. Is cancer small enough to ignore?. The Wall Street Journal (2004) Page A1, December 20
24. Iserson K.V. Ethics, Disease. Book review of: What is Disease? Edited by James M. Humber and Robert F. Almeder. Totowa, NJ. The Humana Press, 1997. N Engl J Med 278 (1997) 1293
25. Aronson J. Medicalization. BMJ 324 (2002) 904
26. Baker S.G. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Natl Cancer Inst 95 (2003) 511-515
27. Kessler L.G., Andersen M.R., and Etzioni R. Much ado about mammography variability. J Natl Cancer Inst 94 (2002) 1346-1347
28. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. Cancer J Clin 55 (2005) 10-30
29. Shibata A., and Whittemore A.S. Re. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 93 (2001) 1109-1110
30. Oliver S.E., Gunnell D., and Donovan J.L. Comparison of trends in prostate cancer mortality in England and Wales and the USA. Lancet 355 (2000) 1788-1789
31. Gottlieb N. San Antonio breast cancer symposium explores DCIS "battleground". J Natl Cancer Inst 92 (2000) 295-297
32. Ernster V.L., Barclay J., Kerlikowske K., et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology, and end results program. Arch Int Med 160 (2000) 953-958
33. Weiss L.A., Pan L., Abney M., et al. The sex-specific genetic architecture of quantitative traits in humans. Nat Genet 38 (2006) 218-222
34. Hubbard R., and Lewontin R.C. Pitfalls of genetic testing (sounding board). N Engl J Med 334 (1996) 1192-1193
35. Temple L.K.F., McLeod R.S., Gallinger S., et al. Defining disease in the genomics era. Science 293 (2001) 807-808
36. Vineis P., Schulte P., and McMichael A.J. Misconceptions about the use of genetic tests in populations. Lancet 357 (2001) 709-712
37. Colhoun H.M., McKeigue P.M., and Smith G.D. Problems of reporting genetic associations with complex outcomes. Lancet 361 (2003) 865-872
38. Hirschhorn J.N., Lohmueller K., Bryne E., et al. A comprehensive review of genetic association studies. Genet Med 4 (2002) 45-61
39. Suita S., Tajiri T., Akazawa K., et al. Mass screening for neuroblastoma at 6 months of age. difficult to justify. J Pediatr Surg 33 (1998) 1674-1678
40. Woods W.G. Screening for neuroblastoma. the final chapters. J Ped Hem/Oncol 25 (2003) 3-4
41. Woods W.G. Substitute "prostate cancer" for "neuroblastoma"?. J Clin Oncol 20 (2002) 1154-1155
42. Yamey G., and Wilkes M. The PSA storm. BMJ 324 (2002) 431
43. LiVolsi V.A. Can we agree to disagree?. Hum Pathol 34 (2003) 1081-1082
44. McGinn C: Looking for a black swan. New York Review of Books Volume XLIX, Number 18:Pages 46-50, November 21, 2002
45. Silverman W.A. Crap-trapping. Lancet 349 (1997) 1471-1472
46. Elmore J.G., Miglioretti D.L., Reisch L.M., et al. Screening mammograms by community radiologists. variability in false-positive rates. J Natl Cancer Inst 94 (2002) 1373-1380
47. Schnitt S.J., Connolly J.L., Tavassoli F.A., et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 16 (1992) 1133-1143
48. Page D.L., Dupont W.D., Jensen R.A., et al. When and to what end do pathologists agree?. J Natl Cancer Inst 90 (1998) 88-89
49. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol 15 (1991) 209-221
50. Boyd W. A Text-Book of Pathology: An Introduction to Medicine. Chaper X (Tumors) (1947), Lea and Febiger, Philadelphia, PA p 249
51. Willis R.A. The Principles of Pathology, Including Bacteriology. ed 2 (1961), Butterworths, Washington DC p 406
52. Albrecht A. Quantum ripples in chaos. Nature 412 (2001) 687-688
53. Calabrese E.J., and Baldwin L.A. Applications of hormesis in toxicology, risk assessment and chemotherapeutics. Trends Pharmacol Sci 23 (2002) 331-337
54. Frumkin H., and Thun M.J. Arsenic (environmental carcinogens). Cancer J Clin 51 (2001) 254-262
55. Kaiser J. Science only one part of arsenic standards. Science 291 (2001) 2533
56. Check E. Screen test. Nature 438 (2005) 733-734
57. Lewens T., and McMillan J. Defining disease (conduct and compassion). Lancet 363 (2004) 664
58. Byrne G.I. The challenge of defining disease. (letter). Science 293 (2001) 1765-1766
59. Resnik D.B. Book review of: The Pursuit of Perfection: The Promise and Perils of Medical Enhancement. By: Sheila M. Rothman and David J. Rothman New York, Pantheon, 2003. N Engl J Med 350 (2004) 1368
60. Reynolds T. Prostate cancer. numbers may not tell the whole story. J Natl Cancer Inst 92 (2000) 1873-1876
61. Gluud C., and Gluud L.L. Evidence based diagnostics. (education and debate). BMJ 330 (2005) 724-726
62. Zivin J.A. Understanding clinical trials. Scientific American (2000) Pages 69-75, April
63. Landers P. Drug firms see costs increase to bring a product to market. The Wall Street Journal (2003) Page B4, December 8
64. Gotsche P.C., and Olsen O. Is screening for breast cancer with mammography justifiable?. Lancet 355 (2000) 129-134
65. Page D.L., Dupont W.D., Rogers L.W., et al. Intraductal carcinoma in situ of the breast. follow-up after biopsy only. Cancer 49 (1982) 751-758
66. Simon R. Evaluating prognostic factor studies. (chapter 4). In: Gospodarowicz M.K., et al. (Ed). Prognostic Factors in Cancer (ed 2), International Union Against Cancer (2001), John Wiley and Sons, New York, NY 49